Biomica to Present at the Microbiome Connect Europe 2022

Rhea-AI Summary

Biomica Ltd., a biopharmaceutical company specializing in microbiome-based therapeutics and a subsidiary of Evogene (NASDAQ: EVGN), will present at Microbiome Connect Europe in Amsterdam on July 6-7, 2022. Dr. Shiri Meshner, VP R&D at Biomica, will participate in a panel discussing gut microbiota's role in cancer therapy on July 6 at 11:30am CET and will present updates on BMC128, a live bacterial consortium for enhancing immune checkpoint therapy, on July 7 at 3:45pm CET. One-on-one meetings with Dr. Meshner are available for interested parties.

REHOVOT, Israel, July 5, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam, Netherlands.

 

The Annual Microbiome Connect Europe is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.

In attendance will be Dr. Shiri Meshner, VP R&D at Biomica, who will be presenting both on behalf of the Company and as part of a panel at the conference.

On July 6, 2022, Dr. Meshner will be part of a panel entitled, Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy, which is scheduled for 11:30am CET.

On July 7, 2022, at 3:45pm CET, Dr. Meshner will be providing an overview and recent updates on Biomica's BMC128 in a talk entitled, BMC128 - A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors.

Dr. Meshner will also be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.

About Biomica

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more information, please visit www.biomicamed.com.

Contacts

Lital Mamon
Head of Marketing and PR
E: IR@evogene.com
T: +972-8-931-2097

Kenny Green
US Investor Relations
E: IR@evogene.com
T: +1 212 378 8040

Logo: https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-microbiome-connect-europe-2022-301580422.html

SOURCE Biomica Ltd.

FAQ

What is Biomica presenting at Microbiome Connect Europe 2022?

Biomica will present updates on its BMC128 therapy and participate in a panel on gut microbiota's role in cancer therapy at Microbiome Connect Europe 2022.

When will Dr. Shiri Meshner speak at the conference?

Dr. Shiri Meshner will speak on July 6 at 11:30am CET and present on July 7 at 3:45pm CET.

What is BMC128 and its purpose?

BMC128 is a rationally designed live bacterial consortium aimed at enhancing immune checkpoint therapy in solid tumors.

Who is attending Microbiome Connect Europe on behalf of Biomica?

Dr. Shiri Meshner, VP R&D at Biomica, will represent the company at the conference.

How can I arrange a meeting with Biomica's representatives at the conference?

Interested parties should contact Biomica's investor or public relations team to arrange one-on-one meetings.